Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Consensus Recommendation of “Buy” by Analysts

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been given a consensus recommendation of “Buy” by the seven research firms that are currently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have covered the stock in the last year is $132.86.

Several equities analysts have recently issued reports on LNTH shares. Truist Financial lifted their price target on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. The Goldman Sachs Group started coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. Finally, JMP Securities reissued a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $104.62 on Wednesday. Lantheus has a 1 year low of $56.44 and a 1 year high of $126.89. The firm has a market cap of $7.16 billion, a P/E ratio of 17.41 and a beta of 0.38. The stock has a fifty day moving average price of $91.13 and a two-hundred day moving average price of $96.88.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. On average, research analysts predict that Lantheus will post 6.01 earnings per share for the current fiscal year.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company’s stock, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.

Institutional Trading of Lantheus

Several hedge funds and other institutional investors have recently modified their holdings of the business. State of New Jersey Common Pension Fund D boosted its position in shares of Lantheus by 0.4% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock worth $2,364,000 after buying an additional 115 shares during the period. Bleakley Financial Group LLC boosted its position in Lantheus by 6.1% during the fourth quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider’s stock valued at $200,000 after purchasing an additional 129 shares during the last quarter. Avantax Advisory Services Inc. boosted its position in Lantheus by 5.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider’s stock valued at $213,000 after purchasing an additional 132 shares during the last quarter. Foundry Partners LLC boosted its position in Lantheus by 4.5% during the fourth quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider’s stock valued at $278,000 after purchasing an additional 133 shares during the last quarter. Finally, UMB Bank n.a. boosted its position in Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.